Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial]

A scorecard of progress towards measles elimination in 15 west African countries, 2001–19: a retrospective, multicountry analysis of national immunisation coverage and surveillance data

(2021) Oghenebrume Wariri et al.   Lancet Global Health

Progress Toward Regional Measles Elimination — Worldwide, 2000–2020

(2021) Meredith G. Dixon et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Global Prevalence and Device Related Causes of Needle Stick Injuries among Health Care Workers: A Systematic Review and Meta-Analysis

(2020) Salehoddin Bouya et al.   Annals of Global Health

Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination

(2020) Paul A Gastañaduy et al.   JOURNAL OF INFECTIOUS DISEASES

Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens

(2019) Michael J. Mina et al.   SCIENCE

Progress Toward Rubella and Congenital Rubella Syndrome Control and Elimination — Worldwide, 2000–2018

(2019) Gavin B. Grant et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

A Microneedle Patch for Measles and Rubella Vaccination Is Immunogenic and Protective in Infant Rhesus Macaques

(2018) Jessica C Joyce et al.   JOURNAL OF INFECTIOUS DISEASES

Measles and Rubella Global Strategic Plan 2012–2020 midterm review

(2018) W.A. Orenstein et al.   VACCINE

Measles and Rubella Global Strategic Plan 2012–2020 midterm review report: Background and summary

(2018) Walter A. Orenstein et al.   VACCINE

Measles

(2017) William J Moss   LANCET

The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial

(2017) Nadine G Rouphael et al.   LANCET

Progress Toward Regional Measles Elimination — Worldwide, 2000–2016

(2017) Alya Dabbagh et al.   MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT

Microneedle patches for vaccination in developing countries

(2016) Jaya Arya et al.   JOURNAL OF CONTROLLED RELEASE

Acceptance of multiple injectable vaccines in a single immunization visit in The Gambia pre and post introduction of inactivated polio vaccine

(2016) Olubukola T. Idoko et al.   VACCINE

Measles Virus Fusion Protein: Structure, Function and Inhibition

(2016) Philippe Plattet et al.   Viruses-Basel

Constraints on the Genetic and Antigenic Variability of Measles Virus

(2016) Shannon Beaty et al.   Viruses-Basel

Assessing the Potential Cost-Effectiveness of Microneedle Patches in Childhood Measles Vaccination Programs: The Case for Further Research and Development

(2016) Bishwa B. Adhikari et al.   Drugs in research & development

Safety and immunogenicity of inactivated poliovirus vaccine when given with measles–rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia

(2016) Ed Clarke et al.   Lancet Global Health

Rubella

(2015) Nathaniel Lambert et al.   LANCET

A microneedle patch containing measles vaccine is immunogenic in non-human primates

(2015) Chris Edens et al.   VACCINE

Mutational Analysis of Measles Virus Suggests Constraints on Antigenic Variation of the Glycoproteins

(2015) Benjamin O. Fulton et al.   Cell Reports

Trends and mortality effects of vitamin A deficiency in children in 138 low-income and middle-income countries between 1991 and 2013: a pooled analysis of population-based surveys

(2015) Gretchen A Stevens et al.   Lancet Global Health

Safety and immunogenicity of dry powder measles vaccine administered by inhalation: A randomized controlled Phase I clinical trial

(2014) Sharad Agarkhedkar et al.   VACCINE

The Receptor-Binding Site of the Measles Virus Hemagglutinin Protein Itself Constitutes a Conserved Neutralizing Epitope

(2013) M. Tahara et al.   JOURNAL OF VIROLOGY

Development of a Bead-Based Multiplex Immunoassay for Simultaneous Quantitative Detection of IgG Serum Antibodies against Measles, Mumps, Rubella, and Varicella-Zoster Virus

(2012) Gaby P. Smits et al.   Clinical and Vaccine Immunology

Impact of birth rate, seasonality and transmission rate on minimum levels of coverage needed for rubella vaccination

(2012) C. J. E. METCALF et al.   EPIDEMIOLOGY AND INFECTION

Cryo-Electron Tomography of Rubella Virus

(2012) A. J. Battisti et al.   JOURNAL OF VIROLOGY

Measles vaccination using a microneedle patch

(2012) Chris Edens et al.   VACCINE

Identification of the Myelin Oligodendrocyte Glycoprotein as a Cellular Receptor for Rubella Virus

(2011) H. Cong et al.   JOURNAL OF VIROLOGY

Adherens junction protein nectin-4 is the epithelial receptor for measles virus

(2011) Michael D. Mühlebach et al.   NATURE

Measles virus-induced suppression of immune responses

(2010) Diane E. Griffin   IMMUNOLOGICAL REVIEWS

Estimates of measles case fatality ratios: a comprehensive review of community-based studies

(2009) L. J Wolfson et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Incubation periods of acute respiratory viral infections: a systematic review

(2009) Justin Lessler et al.   LANCET INFECTIOUS DISEASES